keyword
MENU ▼
Read by QxMD icon Read
search

I-131 Therapy

keyword
https://www.readbyqxmd.com/read/29780557/pd-nanosheets-with-their-surface-coordinated-by-radioactive-iodide-as-a-high-performance-theranostic-nanoagent-for-orthotopic-hepatocellular-carcinoma-imaging-and-cancer-therapy
#1
Mei Chen, Zhide Guo, Qinghua Chen, Jingping Wei, Jingchao Li, Changrong Shi, Duo Xu, Dawang Zhou, Xianzhong Zhang, Nanfeng Zheng
Radiolabeled nanoparticles (NPs), taking advantage of nanotechnology and nuclear medicine, have shown attractive potential for cancer diagnosis and therapy. However, the high background signal in the liver and long-term toxic effects of radioisotopes caused by the nonselective accumulation of radiolabeled nanoparticles in organs have become the major challenges. Here, we report a pH-sensitive multifunctional theranostic platform with radiolabeled Pd nanosheets through a simple mixture of ultra-small Pd nanosheets and radioisotopes utilizing the strong adsorption of 131 I and 125 I on their surfaces (denoted as 131 I-Pd-PEG or 125 I-Pd-PEG)...
May 14, 2018: Chemical Science
https://www.readbyqxmd.com/read/29777005/predictors-of-survival-in-211-patients-with-stage-iv-pulmonary-and-gastroenteropancreatic-mibg-positive-neuroendocrine-tumors-treated-with-i-131-mibg
#2
Ari Kane, Matthew P Thorpe, Jorge D Oldan, Brandon A Howard, Jason Zhu, Michael A Morse, Terence Wong, Neil A Petry, Robert Reiman, Salvador Borges-Neto
Purpose: This retrospective analysis identifies predictors of survival in a cohort of patients with mIBG positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with I-131 mIBG therapy, in order to inform treatment selection and post-treatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from n = 211 P/GEP-NET patients treated with mIBG between 1991-2014. For patients with computed tomography (CT) follow up ( n = 125), imaging response was assessed by Response Evaluation Criteria on Solid Tumors (RECIST) 1...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29766463/predictive-factors-for-the-outcomes-of-initial-i-131-low-dose-ablation-therapy-to-japanese-patients-with-differentiated-thyroid-cancer
#3
Shinji Ito, Shingo Iwano, Katsuhiko Kato, Shinji Naganawa
OBJECTIVE: To identify prognostic factors associated with a low-iodine diet (LID) and the amount of remnant thyroid tissue in Japanese patients with differentiated thyroid cancer (DTC) who received initial I-131 remnant ablation (RAI) using a fixed low dose of I-131 (1110 MBq). PATIENTS AND METHODS: In this prospective study, we enrolled 45 patients. Patients were classified into a self-managed LID group and a strict LID group. We measured the urinary iodine concentration on the day of RAI after patients consumed LID for 2 weeks...
May 15, 2018: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/29761277/treatment-of-differentiated-thyroid-cancer-can-endoscopic-thyroidectomy-via-a-chest-breast-approach-achieve-similar-therapeutic-effects-as-open-surgery
#4
Rui Qu, Jinyi Li, Jingge Yang, Peng Sun, Jian Gong, Cunchuan Wang
BACKGROUND: An analysis of some special factors was performed to further evaluate and discuss whether endoscopic surgery and traditional open surgery have similar therapeutic outcomes for differentiated thyroid cancer (DTC). METHODS: A retrospective study was performed on 76 patients undergoing surgery to treat DTC. Forty patients were treated by endoscopic thyroidectomy via the chest-breast approach (endoscopic group) and thirty-six patients were treated by open surgery (open group)...
May 14, 2018: Surgical Endoscopy
https://www.readbyqxmd.com/read/29755915/unusual-long-survival-with-a-giant-invasive-pheochromocytoma-of-an-incompatible-patient
#5
Asli Nar
Pheochromocytomas (PHEOs) are rare neuroendocrine tumors and about 2-13% of PHEOs are malignant. Predicting malignancy in PHEO cases with invasion but without metastasis is still controversial in the literature. This study presents an unusual long survival with a giant invasive PHEO in an incompatible patient and a review of the literature. In 1989, a 23-year-old female patient was operated for a giant adrenal mass with a pathological final diagnosis of PHEO. Information to the patient's family was provided about the short life span of the patient in the postoperative period because the tumor could not be totally resected...
March 13, 2018: Curēus
https://www.readbyqxmd.com/read/29754217/investigation-of-factors-influencing-radioiodine-131-i-biokinetics-in-patients-with-benign-thyroid-disease-using-nonlinear-mixed-effects-approach
#6
Valentina Topić Vučenović, Zvezdana Rajkovača, Dijana Jelić, Dragi Stanimirović, Goran Vuleta, Branislava Miljković, Katarina Vučićević
PURPOSE: Radioiodine (131 I) therapy is the common treatment option for benign thyroid diseases. The objective of this study was to characterize 131 I biokinetics in patients with benign thyroid disease and to investigate and quantify the influence of patients' demographic and clinical characteristics on intra-thyroidal 131 I kinetics by developing a population model. METHODS: Population pharmacokinetic analysis was performed using a nonlinear mixed effects approach...
May 13, 2018: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29740497/clinical-outcomes-and-associated-factors-of-radioiodine-131-treatment-in-differentiated-thyroid-cancer-with-cervical-lymph-node-metastasis
#7
Chung-Jie Cao, Cheng-Yun Dou, Jiayan Lian, Zhao-Sheng Luan, Wen Zhou, Wenlin Xie, Li Chen, Kehua Zhou, Hong Lai
Cervical lymph node metastasis (CLNM) is common in differentiated thyroid cancer (DTC). Radioiodine-131 (131 I) treatment is recommended for the removal of residual thyroid tissue following thyroidectomy. To date, the effect of 131 I therapy on the outcomes of patients with DTC with CLNM is unclear. The aim of the present study was to evaluate the final outcome of patients with DTC with CLNM according to 131 I administration, and to analyze the factors that may affect clinical outcomes. A total of 357 patients with DTC with CLNM were recruited and divided into three groups: Those who received 2, 3 or 4 doses of 131 I therapy, respectively...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29739021/prognosis-of-transcatheter-closure-compared-with-surgical-repair-of-paravalvular-leak-after-prosthetic-valve-replacement-a-retrospective-comparison
#8
Chun Yang, Yang Liu, Jiayou Tang, Ping Jin, Lanlan Li, Shiqiang Yu, Jian Yang
OBJECTIVE:  Paravalvular leak (PVL) after valve replacement remains clinically challenging. Percutaneous closure is an effective therapy for patients with PVLs because reoperation is associated with high rates of morbidity and mortality. The purpose of this study was to retrospectively compare the clinical outcome of transcatheter closure and surgical repair in patients with a PVL. METHODS:  From January 2000 to May 2016, 131 patients with PVL were treated at three major medical centers in China...
May 8, 2018: Thoracic and Cardiovascular Surgeon
https://www.readbyqxmd.com/read/29734503/improved-survival-after-ltx-associated-acute-gvhd-with-mab-therapy-targeting-il2rab-and-soluble-tnfab-single-center-experience-and-systematic-review
#9
R C Minnee, S Fieuws, I Jochmans, R Aerts, M Sainz Barriga, Y Debaveye, J Maertens, P Vandenberghe, W Laleman, S van der Merwe, C Verslype, D Cassiman, P Ferdinande, F Nevens, J Pirenne, D Monbaliu
Acute graft-versus-host disease (GVHD) after liver transplantation (LTx) is a rare complication with a high mortality rate. Recently, monoclonal antibody (mAb) treatment, specifically with anti-interleukin-2 receptor antibody (IL2RAb) and anti-TNF-α antibody (TNFAb) gained increasing interest. However, evidence is mostly limited to case reports and the efficacy remains unclear. Here, we describe 5 patients with LTx-associated GVHD from our own center, and performed a systematic literature review to evaluate the potential therapeutic benefit of IL2RAb/TNFAb treatment...
May 7, 2018: American Journal of Transplantation
https://www.readbyqxmd.com/read/29717385/determination-of-gamma-camera-calibration-factors-for-quantitation-of-therapeutic-radioisotopes
#10
Wei Zhao, Pedro L Esquinas, Xinchi Hou, Carlos F Uribe, Marjorie Gonzalez, Jean-Mathieu Beauregard, Yuni K Dewaraja, Anna Celler
BACKGROUND: Camera calibration, which translates reconstructed count map into absolute activity map, is a prerequisite procedure for quantitative SPECT imaging. Both planar and tomographic scans using different phantom geometries have been proposed for the determination of the camera calibration factor (CF). However, there is no consensus on which approach is the best. The aim of this study is to evaluate all these calibration methods, compare their performance, and propose a practical and accurate calibration method for SPECT quantitation of therapeutic radioisotopes...
May 2, 2018: EJNMMI Physics
https://www.readbyqxmd.com/read/29713309/nontoxic-goiter-ntg-and-radioiodine-what-do-patients-think-about-it-quality-of-life-in-patients-with-ntg-before-and-after-131-i-therapy
#11
Sonia Kaniuka-Jakubowska, Anna Lewczuk, Mikołaj Majkowicz, Maciej Piskunowicz, Krystyna Mizan-Gross, Adam Zapaśnik, Mariusz Kaszubowski, Piotr Lass, Krzysztof Sworczak
Objective: Despite numerous publications regarding nontoxic goiter (NTG) treatment and an increasing interest in patients' quality of life, few studies present the outcome of 131-I treatment from the patients' perspective. Our study's main aim was to verify whether there is any improvement in life quality following 131-I treatment. Materials and methods: Thirty-five patients with NTG qualified to participate in the study. All patients completed a Thyroid-Related Health-Related Quality of Life (Thy-R-HRQoL) questionnaire created by us and the Medical Outcomes Study 36-item Short Form (SF-36), right before and 1 year after 131-I...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29707123/undetectable-or-low-1-ng-ml-postsurgical-thyroglobulin-values-do-not-rule-out-metastases-in-early-stage-differentiated-thyroid-cancer-patients
#12
Alfredo Campennì, Luca Giovanella, Salvatore Antonio Pignata, Antonio Vento, Angela Alibrandi, Letterio Sturiale, Riccardo Laudicella, Alessio Danilo Comis, Rossella Filice, Giuseppe Giuffrida, Maria Elena Stipo, Salvatore Giovinazzo, Francesco Trimarchi, Rosaria Maddalena Ruggeri, Sergio Baldari
Background: Differentiated thyroid cancer (DTC) work-up is based on (near)total-thyroidectomy plus thyroid remnant ablation (TRA) with 131-radioiodine in many patients, and long-life follow-up. 131 I-post therapy whole body scan (pT-WBS) and serum thyroglobulin (Tg) are used in identifying metastatic patients. Some authors have evaluated the possibility of using post-surgical Tg (ps-Tg) values in deciding for or against TRA. The aim of our study was to verify the diagnostic accuracy of 131 I-pT-WBS and SPECT/CT imaging (post-therapeutic imaging) compared to serum Tg levels in detecting metastases in early stage of DTC patients...
April 3, 2018: Oncotarget
https://www.readbyqxmd.com/read/29684714/microspect-imaging-of-triple-negative-breast-cancer-cell-tumor-xenografted-in-athymic-mice-with-radioiodinated-anti-icam-1-monoclonal-antibody
#13
Linyi You, Xiangyu Wang, Zhide Guo, Deliang Zhang, Pu Zhang, Jindian Li, Xinhui Su, Weimin Pan, Xianzhong Zhang
Intercellular adhesion molecule-1(ICAM-1) is a potential molecular target and biomarker for triple negative breast cancer (TNBC) therapy and diagnosis. In this study, aICAM-1 was radioiodinated with 125 I/131 I in high radiochemical yield and the probes for TNBC tumor targeting and radioimmunotherapy were evaluated in tumor-bearing mice. High and specific accumulation of 125 I-aICAM1 in TNBC MDA-MB-231 tumor was observed in SPECT imaging and the tumor grew was inhibited obviously by 131 I-aICAM1. Thus, the radioiodinated aICAM1 could serve as potential agents for TNBC theranostics...
April 4, 2018: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/29684277/immunopet-imaging-of-endogenous-and-transfected-prolactin-receptor-tumor-xenografts
#14
Sarah M Cheal, Shutian Ruan, Darren R Veach, Valerie A Longo, Blesida J Punzalan, Jiong Wu, Edward K Fung, Marcus P Kelly, Jessica R Kirshner, Jason T Giurleo, George Ehrlich, Amy Q Han, Gavin Thurston, William C Olson, Pat B Zanzonico, Steven M Larson, Jorge A Carrasquillo
OBJECTIVE: Antibodies labeled with positron-emitting isotopes have been used for tumor detection, predicting which patients may respond to tumor antigen-directed therapy, and assessing pharmacodynamic effects of drug interventions. Prolactin receptor (PRLR) is overexpressed in breast and prostate cancers and is a new target for cancer therapy. We evaluated REGN2878, an anti-PRLR monoclonal antibody, as an immunoPET reagent. METHODS: REGN2878 was labeled with Zr-89 after conjugation with desferrioxamine B or labeled with I-131/I-124...
April 23, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29682133/autosomal-dominant-polycystic-kidney-disease-a-potential-mistake-in-the-interpretation-of-radioiodine-whole-body-scintigraphy
#15
Leila Kalhor
There are a few case reports of renal cysts demonstrating radioiodine uptake on scintigraphy. In this case, we report a 49-year-old man who had undergone total thyroidectomy and had been treated with radioiodine. After conventional levothyroxine withdrawal, the patient underwent thyroid remnant ablation by oral administration of 125 mci 131 I. Seven days later, post-therapy whole-body scan demonstrated thyroid remnant tissue and bilaterally multifocal radioiodine uptake in the upper abdomen. By ultrasonography and abdominal computed tomography scan, the iodine uptake was proven to be due to the accumulation of 131 I in bilateral polycystic kidney disease...
April 2018: Radiology Case Reports
https://www.readbyqxmd.com/read/29681781/preclinical-evaluation-of-radioiodinated-hoechst-33258-for-early-prediction-of-tumor-response-to-treatment-of-vascular-disrupting-agents
#16
Dongjian Zhang, Meng Gao, Nan Yao, Cuihua Jiang, Wei Liu, Tiannv Li, Shaoli Song, Dejian Huang, Zhiqi Yin, Yunliang Qiu, Qiaomei Jin
This study aimed to explore the use of 131 I-Hoechst 33258 (131 I-H33258) for early prediction of tumor response to vascular-disrupting agents (VDAs) with combretastatin-A4 phosphate (CA4P) as a representative. Necrosis avidity of 131 I-H33258 was evaluated in mouse models with muscle necrosis and blocking was used to confirm the tracer specificity. Therapy response was evaluated by 131 I-H33258 SPECT/CT imaging 24 h after CA4P therapy in W256 tumor-bearing rats. Radiotracer uptake in tumors was validated ex vivo using γ -counting, autoradiography, and histopathological staining...
2018: Contrast Media & Molecular Imaging
https://www.readbyqxmd.com/read/29664794/positive-surgical-margins-in-favorable-stage-differentiated-thyroid-cancer
#17
Catherine E Mercado, Peter A Drew, Christopher G Morris, Peter T Dziegielewski, William M Mendenhall, Robert J Amdur
OBJECTIVE: The significance of positive margin in favorable-stage well-differentiated thyroid cancer is controversial. We report outcomes of positive-margin patients with a matched-pair comparison to a negative-margin group. MATERIALS AND METHODS: A total of 25 patients with classic-histology papillary or follicular carcinoma, total thyroidectomy +/- node dissection, stage T1-3N0-1bM0, positive surgical margin at primary site, adjuvant radioactive iodine (I-131), and age older than 18 years were treated between 2003 and 2013...
April 16, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29664714/randomized-phase-ii-trial-of-fulvestrant-plus-everolimus-or-placebo-in-postmenopausal-women-with-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-metastatic-breast-cancer-resistant-to-aromatase-inhibitor-therapy-results-of-pre0102
#18
Noah Kornblum, Fengmin Zhao, Judith Manola, Paula Klein, Bhuvaneswari Ramaswamy, Adam Brufsky, Phillip J Stella, Brian Burnette, Melinda Telli, Della F Makower, Puneet Cheema, Cristina I Truica, Antonio C Wolff, Gamini S Soori, Barbara Haley, Timothy R Wassenaar, Lori J Goldstein, Kathy D Miller, Joseph A Sparano
Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian target of rapamycin pathway, a mechanism of resistance to anti-estrogen therapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that everolimus plus the selective ER downregulator fulvestrant would be more efficacious than fulvestrant alone in ER-positive metastatic breast cancer resistant to aromatase inhibitor (AI) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase II study included 131 postmenopausal women with ER-positive, human epidermal growth factor receptor 2-negative, AI-resistant metastatic breast cancer randomly assigned to fulvestrant (500 mg days 1 and 15 of cycle 1, then day 1 of cycles 2 and beyond) plus everolimus or placebo...
April 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29658363/therapy-of-cervical-cancer-using-131-i-labeled-nanoparticles
#19
Wei Li, Danyang Sun, Ning Li, Yiming Shen, Yiming Hu, Jian Tan
Objective To evaluate the effectiveness of two kinds of Arg-Gly-Asp (RGD)-targeted 131 I-containing nanoliposomes for the treatment of cervical cancer in vitro and in vivo. Methods The nanoparticle liposomes designated RGD-131 I-tyrosine peptide chain (TPC)-L and 131 I-RGD-L were prepared. The emulsion solvent evaporation method was used to encapsulate the polypeptide into liposomes. The quantity of entrapped polypeptide was measured using UV spectrophotometry. The labeling rates, radiochemical purities, and total radioactivities were measured using paper chromatography...
January 1, 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29645065/-131-i-mibg-therapy-of-malignant-pheochromocytoma-and-paraganglioma-tumors-a-single-center-study
#20
Agnieszka Kotecka-Blicharz, Kornelia Hasse-Lazar, Daria Handkiewicz-Junak, Tomasz Gawlik, Agnieszka Pawlaczek, Małgorzata Oczko-Wojciechowska, Barbara Michalik, Sylwia Szpak-Ulczok, Jolanta Krajewska, Beata Jurecka-Lubieniecka, Barbara Jarząb
INTRODUCTION: Pheochromocytomas and paragangliomas are rare tumors deriving from chromaffin cells of adrenal medulla or paraganglia. They are usually benign but 10-35% of them present malignant behavior. The aim of the study was to evaluate the efficacy and safety of 131-I MIBG therapy in malignant pheochromocytoma /paraganglioma patients (MPPGL). MATERIAL AND METHODS: 18 patients (7 women and 11 men) were included in this study. Between 2002 and 2016 they underwent 131-I MIBG therapy because of MPPGL and their medical data were analyzed retrospectively...
April 12, 2018: Endokrynologia Polska
keyword
keyword
97180
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"